| Species |
Human |
| Protein Construction |
IL-1RA (Arg26-Glu177)
Accession # P18510-1 |
|
| Purity |
> 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Biological Activity |
Measured by its ability to inhibit IL-1 beta induced NF-kB signaling in 293-IL1 Res cells. The ED50 for this effect is 13.2 ng/mL. |
| Expression System |
E. coli |
| Theoretical Molecular Weight |
17.3 kDa |
| N-terminal Sequence Analysis |
The sequence of the first five N-terminal amino acids was determined and found to be Met-Arg-Pro-Ser-Gly. |
| Apparent Molecular Weight |
~18 kDa, on SDS-PAGE under non-reducing conditions. |
| Formulation |
Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in distilled water up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Interleukin-1 receptor antagonist (IL-1ra) is a member of the IL-1 family. Endogenous IL-1ra is produced in numerous animal disease models as well as in human autoimmune and chronic inflammatory diseases. It binds to IL-1 receptors in competition with IL-1, but does not elicit intracellular response from this binding. Its role in counteracting the proinflammatory effects of IL-1 is being studied by numerous research groups. IL-4 and IL-13 have been shown to amplify the stimulatory effect of IL1-beta on the production of soluble and intracellular forms of IL1-ra. The regulated expression of IL1ra in various cell types has been shown to be influenced by cytokines. In synovial fibroblasts the synthesis of IL-1ra is markedly enhanced by IL-1, TNF-alpha, or PDGF. |
| Synonyms |
IL-1ra; IL1 Receptor Antagonist; Interleukin-1 Receptor Antagonist; Interleukin1 Receptor Antagonist |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
